RPR107393 free base

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: RPR107393 free base
• 英文别名: 3-(4-quinolin-6-ylphenyl)-1-azabicyclo[2.2.2]octan-3-ol
• 化学式: C₂₂H₂₂N₂O
• 分子量: 330.4
• InChiKey: JICDBMXIQNEXKV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  25
• 可旋转键数：
  2
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  36.4
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• Skeletal muscle protecting agent
  申请人：Tozawa Ryuichi

  公开号：US20080113965A1

  公开（公告）日：2008-05-15

  The present invention provides a novel drug which is useful as a skeletal muscle protecting agent comprising a compound having inhibitory activity against squalene synthase or a salt thereof, or a prodrug thereof.
• REMEDY FOR XANTHOMA
  申请人：Shiomi Masashi

  公开号：US20090082333A1

  公开（公告）日：2009-03-26

  A preventive/remedy for xanthoma which contains a compound having an inhibitory effect on squalene synthase, its prodrug or its salt.
• Crp Lowering Agent
  申请人：Imura Yoshimi

  公开号：US20090118255A1

  公开（公告）日：2009-05-07

  The present invention provides a novel drug which is useful as a preventive and/or therapeutic agent for various diseases involved in elevation of CRP level, in particular, inflammatory disease and cancer comprising a compound having inhibitory activity against squalene synthase or a salt thereof, or a prodrug thereof.
• Novel Method of Treating Hyperlipidemia
  申请人：Nishimoto Tomoyuki

  公开号：US20090209510A1

  公开（公告）日：2009-08-20

  A pharmaceutical composition useful for a prevention and/or treatment of hyperlipidemia, which comprises combining an effective amount of squalene synthase inhibitor and HMG-CoA reductase inhibitor is provided.
• INHIBITION OF ISOPRENOID BIOSYNTHETIC PATHWAYS TO TREAT NEUROINFLAMMATORY DISORDERS
  申请人：TABACZYNSKI David A.

  公开号：US20160303146A1

  公开（公告）日：2016-10-20

  This invention provides methods and pharmaceutical compositions that can treat neuroinflammatory disease by reducing the production of pyrophosphate intermediates produced during the biosynthesis of isoprenoids. The pyrophosphate compounds being inhibited are normally produced through the mevalonate and non-mevalonate pathways of the host vertebrate organisms and their symbiotic and pathogenic microorganisms. The methods involve administering to a patient an inhibitor of the mevalonate-dependent pathway, an inhibitor of the non-mevalonate pathway, or combination of such inhibitors.